Court Rules Teva Did Not Infringe on Corcept Therapeutics’ Patents

A New Jersey judge ruled last week that Teva Pharmaceuticals did not infringe on two Corcept patents for its Cushing’s syndrome drug Korlym (mifepristone).

In a lawsuit filed in 2018 in the U.S. District Court District of New Jersey, Corcept alleged that Teva’s submission of an ANDA for Korlym prior to the expiration of its patents constitutes infringement. Following years of legal wrangling, the issues remaining before the court primarily were patented instructions on safely coadministering mifepristone with CYP3A inhibitors (also used to treat Cushings) such as erythromycin, ketoconazole and verapamil.

In its Dec. 29 opinion, the court stated that Corcept did not meet “its burden of proving induced infringement” and did not demonstrate that “that direct infringement of Corcept’s claims was more likely if Teva’s generic mifepristone product were placed on the market.” Corcept said it plans to appeal the court’s decision.

Read the Court’s opinion here.

To read the whole story, click here to subscribe.

Related Topics